Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
Drug distributor McKesson Corp. says its contract with the federal government to supply prescription medications to the Cherokee Nation may protect it from liability for the opioid epidemic.
According to the drug distributor’s filing in federal court, McKesson acted under the direction of a federal government officer for at least some of the allegedly illegal acts the Cherokee Nation claims.
The nation seeks to hold McKesson and other drug retailers and distributors responsible for the epidemic, which could mean significant potential financial liability, particularly given the suit is just one of more than 500 actions filed around the country by counties, cities, Indian tribes, and other entities seeking to recover damages on the basis of expenses they have incurred in dealing with opioid addiction.
McKesson’s invocation of its supply contract with the federal government could be a successful defense to the nation’s claims that McKesson enabled prescription opioids to fall into illegal channels, didn’t alert regulators to suspiciously large quantity orders, and used financial incentives to increase opioid sales.
A lot is at stake: McKesson recorded $198.5 billion in annual revenue for its most recent fiscal year, according to data on Bloomberg Law.
McKesson’s supply contract, a pharmaceutical prime vendor (PPV) contract with the Veterans’ Administration (VA), is governed by federal law and overseen by a federal contracting officer, McKesson said in its court filing.
“This PPV Contract obligates McKesson to supply prescription medications to Tribal facilities when they are ordered by the Indian Health Service (IHS) through the PPV Contract and likewise to supply the VA facilities in and around the Tribal Area,” it said.
The government contractor defense “provides immunity to contractors for conduct that complies with the specifications of a federal contract,” McKesson said. Although McKesson raised the defense in support of its argument that a federal court and not state court should hear the nation’s suit, its filing makes clear the company meets the minimal burden of sufficiently alleging the government contractor defense.
Whether McKesson’s defense will ultimately succeed is an open question.
The Cherokee Nation, in its own filing seeking to send its case from federal court back to state court, is calling McKesson’s potential government contractor defense into question.
“McKesson’s brief is devoid of any explanation how its potential exposure to liability in this lawsuit is ‘because of’ its compliance with a government contract—which is not surprising, since the [PPV] Contract attached to McKesson’s brief actually prohibits the misconduct at issue here,” the nation said in the filing.
“McKesson’s statement that the federal government somehow directed its actions in this case is patently untrue, and it is puzzling how McKesson can even make that claim in light of the federal government’s $150 million fine against McKesson last year for conduct substantially similar to what the Cherokee Nation has alleged in this lawsuit,” it said.
In 2017, McKesson paid a $150 million fine to the federal government for failing to report certain opioid shipments to the Drug Enforcement Administration.
In addition to McKesson, defendants in the nation’s suit also include Cardinal Health Inc., AmerisourceBergen, CVS Health, Walgreens Boots Alliance Inc., and Wal-Mart Stores Inc., all of whom are accused of failing to monitor their supply chain under the Controlled Substances Act and of violating the Cherokee Nation’s Unfair Trade and Deceptive Practices Act.
The case is The Cherokee Nation v. McKesson Corp. , E.D. Okla., No. , E.D. Okla., No. 18-CV-00056, 2/26/18, complaint filed 2/26/18 .
To contact the reporter on this story: Dana A. Elfin in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Randy Kubetin at email@example.com
Copyright © 2018 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)